\nHyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop<\/i>\u00ae system, the world\u2019s first FDA-cleared portable magnetic resonance brain imaging system, has announced the commencement of an international, multi-site observational study, ACTION PMR (ACuTe Ischemic strOke detectioN with Portable MR). To support its acute stroke care initiatives, Hyperfine Inc. has formed an advisory board of world-renowned stroke experts.<\/p>\n
This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20230711397384\/en\/<\/a><\/p>\n (Photo: Business Wire)<\/p>\n<\/div>\n \nAs a prospective, international, multi-site observational study, ACTION PMR aims to examine the integration of brain imaging with the Swoop<\/i>\u00ae system into the stroke diagnosis and treatment workflow. The goal is to use point-of-care brain imaging to identify strokes and viable brain tissue that can be saved.<\/p>\n \nMRI scans, which are more precise than CT scans, are recommended for diagnosing acute ischemic stroke within twelve hours of symptom onset by the American Academy of Neuroradiology. However, the limited availability of MRI scanners near acute care settings in many hospitals highlights the need for point-of-care MR brain imaging.<\/p>\n \n\u201cThe ACTION PMR study has the potential to improve stroke treatment all over the world, with the Swoop<\/i>\u00aesystem assisting clinicians in imaging brain tissue and making timely diagnoses which could lead to the implementation of more effective treatments and help to facilitate better patient outcomes,\u201d says Dr. Khan Siddiqui, Hyperfine, Inc. Chief Medical Officer and Chief Strategy Officer.<\/p>\n \nFour investigators from leading institutions will lead the study: Dr. W. Taylor Kimberly of Massachusetts General Hospital, Dr. Adnan Siddiqui of the University at Buffalo, Dr. Vivien Lee of the Ohio State University Wexner Medical Center, and Dr. Keith Muir of the University of Glasgow.<\/p>\n \n\u201cRefining stroke diagnosis and care is central to all we do; as such, our research will focus on patients who don\u2019t immediately qualify for thrombectomy,\u201d says Dr. Taylor Kimberly of Massachusetts General Hospital. \u201cWe hope this study may contribute to timelier diagnoses, paving the way for improved patient outcomes.\u201d<\/p>\n \nAlongside the ACTION PMR study, the newly formed stroke advisory board, comprised of experts in the field, will provide insights and experiences to guide and define the impact the Swoop<\/i>\u00ae system can have in the fast-evolving field of acute stroke care.<\/p>\n \nMaria Sainz, Hyperfine, Inc. President and CEO, adds, “There is a significant unmet need in stroke imaging and workflow representing a very compelling incremental opportunity for Hyperfine, Inc. Our ambition is to enable innovative and readily accessible brain imaging solutions that enhance the chances of recovery for every patient. ACTION PMR is an important project for us, and we are honored to be working with our distinguished clinical investigators and stroke advisors to navigate the challenges and opportunities in stroke care and formulate the role the Swoop<\/i>\u00ae system can play in acute stroke workflow.\u201d<\/p>\n \nFor more information about the Swoop\u00ae<\/i>Portable MR Imaging\u00ae<\/i> system, please visit hyperfine.io<\/a>.<\/p>\n About Hyperfine, Inc. and the Swoop\u00ae<\/i>Portable MR Imaging\u00ae<\/i> System<\/b><\/p>\n \nHyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking medical technology company that created the Swoop\u00ae<\/i> system, the world\u2019s first FDA-cleared portable magnetic resonance imaging (MRI) system capable of providing brain imaging at the point of care. The Swoop\u00ae<\/i> system received initial U.S. Food and Drug Administration (FDA) clearance in 2020 as a bedside magnetic resonance imaging device for producing images that display the internal structure of the head where a full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. The Swoop\u00ae<\/i> system has been approved for brain imaging in several countries, including Canada and Australia, has UKCA certification in the United Kingdom, CE certification in the European Union, and is also available in New Zealand.<\/p>\n \nThe mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging and data solutions. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop\u00ae<\/i> system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. Traditionally, access to costly, stationary, conventional MRI technology can be inconvenient or not available when needed most. With the portable, ultra-low-field Swoop\u00ae<\/i> system, Hyperfine, Inc. is redefining the neuroimaging workflow by bringing brain imaging to the patient\u2019s bedside. For more information, visit hyperfine.io<\/a>.<\/p>\n \nHyperfine, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.<\/p>\n Forward-Looking Statements<\/strong><\/p>\n \nThis press release includes \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. Hyperfine, Inc. (\u201cthe Company\u201d)\u2019s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as \u201cexpect,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cbudget,\u201d \u201cforecast,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cbelieves,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the goals, the Company\u2019s commercial plans, the benefits of the Company\u2019s products and services, and the Company\u2019s future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company\u2019s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company\u2019s product development and commercialization activities, including the degree that the Swoop\u00ae<\/i> system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company\u2019s business; the inability to maintain the listing of the Company\u2019s Class A common stock on the Nasdaq; the Company\u2019s inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company\u2019s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company\u2019s products and services and reimbursement for medical procedures conducted using the Company\u2019s products and services; the Company\u2019s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company\u2019s financial performance; and other risks and uncertainties indicated from time to time in Company\u2019s filings with the Securities and Exchange Commission, including those under \u201cRisk Factors\u201d therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230711397384\/en\/<\/a><\/span><\/p>\n Media Contact Investor Contact KEYWORDS:<\/b> Connecticut United States North America<\/p>\n INDUSTRY KEYWORDS:<\/b> Health Medical Devices Neurology Radiology Clinical Trials Research Science<\/p>\n![\"(Photo:](\"https:\/\/mms.businesswire.com\/media\/20230711397384\/en\/1837950\/4\/52686691096_c7e9d9b526_o.jpg\")
<\/p>\n<\/p>\n
\n<\/strong>
Jessica Stebing
\n
Health+Commerce
\n
jstebing@healthandcommerce.com<\/a><\/p>\n
\n<\/strong>
Marissa Bych
\n
Gilmartin Group LLC
\n
marissa@gilmartinir.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20230711397384\/en\/1837319\/3\/Logomark_in_FullColor.jpg\")
<\/td>\n<\/tr>\n![\"Photo\"](\"https:\/\/mms.businesswire.com\/media\/20230711397384\/en\/1837950\/3\/52686691096_c7e9d9b526_o.jpg\")
<\/td>\n<\/tr>\n